FDA will meet to review behavior changes, psychiatric risks of Pfizer's stop-smoking drug

  • by: MATTHEW PERRONE , Associated Press
  • Updated: April 25, 2014 - 4:54 PM

WASHINGTON — The Food and Drug Administration announced Friday it will hold a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT